Improving the Clinical Utility of Umbilical Cord Blood Donations by Ex-Vivo Expansion Using Mesenchymal Stromal Cells

通过使用间充质基质细胞进行离体扩增来提高脐带血捐赠的临床效用

• 批准号: 130991
• 金额: $ 15.82万
• 依托单位: ROSLIN CELLS LIMITED
• 依托单位国家: 英国
• 项目类别: Feasibility Studies
• 财政年份: 2012
• 资助国家: 英国
• 起止时间: 2012 至 无数据
• 项目状态: 已结题
• 来源: https://gtr.ukri.org/projects?ref=130991
• 关键词: Improving; Clinical; Utility; Umbilical; Cord

This project will assess the feasibility of improving the clinical utility of umbilical cord blood (UCB) through ex vivo expansion mediated by co-culture with mesenchymal stromal cells (MSCs). We have patented technology for the production pluripotent stem cell derived MSCs, which means that we can supply these cells in almost limitless quantities. The haematopoietic stem and progenitor cells found in UCB are of immense clinical value and our MSCs exhibit several advantages over bone marrow derived MSCs. Over half of all UCB units cannot be used clinically as they lack sufficient quantities of haematopoietic stem or progenitor cells. This feasibility project will build on patented and other prior work and create the opportunity to establish a significant business with important clinical impact.

该项目将评估通过与间充质基质细胞(MSCs)共培养介导的体外扩增来提高脐带血(UCB)临床实用性的可行性。我们拥有生产多能干细胞来源的MSCs的专利技术，这意味着我们可以几乎无限地供应这些细胞。在脐带血中发现的造血干/祖细胞具有巨大的临床价值，我们的MSCs表现出比骨髓来源的MSCs更多的优势。超过一半的脐带血单位不能用于临床，因为它们缺乏足够数量的造血干或祖细胞。这一可行性项目将建立在专利和其他先前工作的基础上，并创造机会建立具有重要临床影响的重要业务。